冠動脈ステントを施す女性と男性の予後要因と結果の違い
J Mehilli1, A Kastrati, J Dirschinger
1Deutsches Herzzentrum, Lazarettstr 36, 80636 Munich, Germany.
JAMA
|October 12, 2000
まとめ
冠動脈疾患 (CAD) の女性で冠動脈ステントを施しても,1年後に男性と同様の結果が出ます. しかし,女性はより高い早期リスクに直面し,糖尿病は,年齢がより重要な男性とは異なり,主要な予後要因である.
科学分野:
- 心臓病学 心臓病学
- 介入性心臓病学 介入性心臓病学
- 性別に基づく医学とは
背景:
- 冠動脈疾患 (CAD) の管理は,伝統的に男性特有のリスクに焦点を当てていました.
- CADの女性は,男性と比較して,介入後の結果が悪化することがあります.
- 冠動脈ステントの性に基づく結果への影響については,さらなる調査が必要である.
研究 の 目的:
- 予後要因における性差異を調査する.
- 冠動脈ステント設置後の男性と女性の早期と遅い結果を比較する.
主な方法:
- 1001人の女性と3263人の男性を対象とした初期コホート研究.
- 冠動脈ステントの設置は1992年5月から1998年12月にかけて行われた.
- 死亡率と非致死性心筋梗塞の合併イベント率は,30日と1年後に評価されました.
主要な成果:
- 女性は高齢で,男性よりも糖尿病,高血圧,高コレステロール血症の罹患率が高かった.
- 女性では,死亡または心筋梗塞の早期リスクが増加した (3.1%対1.8%で30日;調整HR2.02).
- 1年目には,男女差で結果が似ていた (6.0%対5.8%;調整HR1.06),糖尿病が女性にとって,年齢が男性にとって重要な要因であった.
結論:
- 冠動脈ステントの1年後の結果は,CADの女性と男性で比較できます.
- ベースラインの特徴,臨床経過,および予後要因において,有意な性別差異が存在する.
- これらの違いを理解することは,女性におけるパーソナライズされたCAD管理に不可欠です.
関連する概念動画
Coronary Artery Disease I: Introduction
1.7K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Coronary Artery Disease IV: Preventive Measures
866
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
866
Coronary Artery Disease V: Interprofessional Care
423
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
423
Acute Coronary Syndrome I: Introduction
1.8K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.8K
Acute Coronary Syndrome III: Diagnostic Studies
468
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
468
Acute Coronary Syndrome IV: Interprofessional Care
490
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
490


